The safety and efficacy of baclofen to reduce alcohol use in veterans with chronic hepatitis C: a randomized controlled trial

Addiction

Volumn 112, Issue 7, 2017, Pages 1173-1183

  Hauser, Peter ^a,b,c,d   Fuller, Bret ^e,f   Ho, Samuel B ^g,h   Thuras, Paul ^i,j   Kern, Shira ^a   Dieperink, Eric ^i,j  

^a VA LONG BEACH HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d VISN 22 Network Office   (United States)

^e PORTLAND VA MEDICAL CENTER   (United States)

^f OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^g VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^h UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

ⁱ A VA HSR and D Center of Excellence   (United States)

^j UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

more..

Author keywords

Alcohol use disorders; baclofen; GABA beta receptor agonist; hepatitis C; randomized clinical trial; veterans

Indexed keywords

4 AMINOBUTYRIC ACID B RECEPTOR STIMULATING AGENT; BACLOFEN;

ALCOHOLISM; CHRONIC HEPATITIS C; COMPLICATION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; HUMAN; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME; VETERAN;

ALCOHOLISM; BACLOFEN; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; GABA-B RECEPTOR AGONISTS; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME; VETERANS;

EID: 85017115255     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/add.13787     Document Type: Article

References (44)

1. World Health Organization. Global Status Report on Alcohol and Health [Internet]. Geneva: World Health Organization; 2014. Available at: http://www.who.int/iris/bitstream/10665/112736/1/9789240692763_eng.pdf?ua=1 (accessed 16 April 2016) (Archived at http://www.webcitation.org/6ockvp4jq on 28 February 2017).
2. Hasin D. S., Stinson F. S., Ogburn E., Grant B. F. Prevalence, correlates, disability, and comorbidity of DSM-IV alcohol abuse and dependence in the United States: results from the National Epidemiologic Survey on alcohol and related conditions. Arch Gen Psychiatry 2007; 64: 830–842.
3. Grant B. F., Goldstein R. B., Saha T. D., Chou S. P., Jung J., Zhang H. et al. Epidemiology of DSM-5 alcohol use disorder: results from the National Epidemiologic Survey on alcohol and related conditions III. JAMA Psychiatry 2015; 72: 757–766.
4. Dawson D. A., Grant B. F., Stinson F. S., Chou P. S., Huang B., Ruan W. Recovery from DSM-IV alcohol dependence: United States, 2001–2002. Addiction 2005; 100: 281–292.
5. Mark T. L., Kassed C. A., Vandivort-Warren R., Levit K. R., Kranzler H. R. Alcohol and opioid dependence medications: prescription trends, overall and by physician specialty. Drug Alcohol Depend 2009; 99: 345–349.
6. Harris A. H., Kivlahan D. R., Bowe T., Humphreys K. N. Pharmacotherapy of alcohol use disorders in the Veterans Health Administration. Psychiatr Serv 2010; 61: 392–398.
7. Harris A. H., Oliva E., Bowe T., Humphreys K. N., Kivlahan D. R., Trafton J. A. Pharmacotherapy of alcohol use disorders by the Veterans Health Administration: patterns of receipt and persistence. Psychiatr Serv 2012; 63: 679–685.
8. Maisel N. C., Blodgett J. C., Wilbourne P. L., Humphreys K., Finney J. W. Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful? Addiction 2013; 108: 275–293.
9. Berger L., Fisher M., Brondino M., Bohn M., Gwyther R., Longo L. et al. Efficacy of acamprosate for alcohol dependence in a family medicine setting in the United States: a randomized, double-blind, placebo-controlled study. Alcohol Clin Exp Res 2013; 37: 668–674.
10. Maust D. T., Mavandadi S., Klaus J., Oslin D. W. Missed opportunities: fewer service referrals after positive alcohol misuse screens in VA primary care. Psychiatr Serv 2011; 62: 310–312.
11. Berglund M., Thelander S., Salaspuro M., Franck J., Andréasson S., Öjehagen A. Treatment of alcohol abuse: an evidence-based review. Alcohol Clin Exp Res 2003; 27: 1645–1656.
12. Krystal J. H., Cramer J. A., Krol W. F., Kirk G. F., Rosenheck R. A. Naltrexone in the treatment of alcohol dependence. N Engl J Med 2001; 345: 1734–1739.
13. Bouza C., Angeles M., Ana M., María A. J. Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review. Addiction 2004; 99: 811–828.
14. Mann K., Lehert P., Morgan M. Y. The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: results of a meta-analysis. Alcohol Clin Exp Res 2004; 28: 51–63.
15. Srisurapanont M., Jarusuraisin N. Naltrexone for the treatment of alcoholism: a meta-analysis of randomized controlled trials. Int J Neuropsychopharmacol 2005; 8: 267–280.
16. Dodd P. R., Beckman A. M., Davidson M. S., Wilce P. A. Gluatmate-mediated transmission, alcohol and alcoholism. Neurochem Int 2000; 37: 509–533.
17. Colombo G., Vacca G., Serra S., Brunetti G., Carai M. A., Gessa G. L. Baclofen suppresses motivation to consume alcohol in rats. Psychopharmacology (Berlin) 2003; 167: 221–224.
18. Davidoff R. A. Antispasticity drugs: mechanisms of action. Ann Neurol 1985; 17: 107–116.
19. Addolorato G., Caputo F., Capristo E., Domenicali M., Bernardi M., Janiri L. et al. Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomized controlled study. Alcohol Alcohol 2002; 37: 504–508.
20. Addolorato G., Leggio L., Abenavoli L., Agabio R., Caputo F., Capristo E. et al. Baclofen in the treatment of alcohol withdrawal syndrome: a comparative study vs diazepam. Am J Med 2006; 119: 276.e13-8.
21. Addolorato G., Leggio L., Ferrulli A., Cardone S., Vonghia L., Mirijello A. et al. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomized, double-blind controlled study. Lancet 2007; 370: 1915–1922.
22. Agabio R., Preti A., Gessa G. L. Efficacy and tolerability of baclofen in substance use disorders: a systematic review. Eur Addict Res 2013; 19: 325–345.
23. Garbutt J. C., Kampov-Polevoy A. B., Gallop R., Kalka-Juhl L., Flannery B. A. Efficacy and safety of baclofen for alcohol dependence: a randomized, double-blind, placebo-controlled trial. Alcohol Clin Exp Res 2010; 34: 1849–1857.
24. Ponizovsky A. M., Rosca P., Aronovich E., Weizman A., Grinshpoon A. Baclofen as add-on to standard psychosocial treatment for alcohol dependence: a randomized, double-blind, placebo-controlled trial with 1 year follow-up. J Subst Abuse Treat 2015; 52: 24–30.
25. Bush K., Kivlahan D. R., McDonell M. B., Fihn S. D., Bradley K. A. The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Arch Intern Med 1998; 158: 1789–1795.
26. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR. Washington, DC: American Psychiatric Association; 2000.
27. First M. B. Research Version of the Structured Clinical Interview for DSM-IV-TR AXIS I Disorders: (SCID-1). New York: New York State Psychiatric Institute; 2005.
28. Sobell L. C., Sobell M. B. Timeline follow-back: a technique for assessing self-reported alcohol consumption. In: Litten R. Z., Allen J., editors. Measuring Alcohol Consumption: Psychosocial and Biological Methods. Totowa, NJ: Humana Press; 1992, pp. 41–72.
29. Sobell L. C., Brown J., Leo G. I., Sobell M. B. The reliability of the alcohol timeline followback when administered by telephone and by computer. Drug Alcohol Depend 1996; 42: 49–54.
30. Anton R. F., Moak D. H., Latham P. K. The obsessive compulsive drinking scale: a new method of assessing outcome in alcoholism treatment studies. Arch Gen Psychiatry 1996; 53: 225–231.
31. Derogatis L. R., Melisaratos N. The brief symptom inventory: an introductory report. Psychol Med 1983; 13: 595–605.
32. Beck A. T., Steer R. A., Brown G. K. Beck Depression Inventory–2nd edn (BDI-II). San Antonio, TX: Psychological Corporation; 1996.
33. Norris F. H., Hamblen J. L. Standardized self-report measures of civilian trauma and PTSD. In: Wilson J. P., Keane T. M., editors. Assessing Psychological Trauma and PTSD, 2nd edn. New York: Guilford Press; 2004, pp. 63–102.
34. Johnson B. A., DiClemente C. C., Ait-Daoud N., Stoks S. M., Johnson B. A., Ruiz P. et al. Brief behavioral compliance enhancement treatment (BBCET) manual. In: Handbook of Clinical Alcoholism Treatment. Baltimore: Lippincott Williams & Wilkins; 2003, pp. 282–301.
35. US Department of Health and Human Services/FDA, Center for Drug Evaluation and Research. Alcoholism: Developing Drugs for Treatment Guidance for Industry [Internet]. Rockville: Food and Drug and Administration; 2015. Available at: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm433618.pdf (accessed 16 April 2016) (Archived at http://www.webcitation.org/6jfNMGeSW on 10 August 2016).
36. Falk D., Wang X. Q., Liu L., Fertig J., Mattson M., Ryan M. et al. Percentage of subjects with no heavy drinking days: evaluation as an efficacy endpoint for alcohol clinical trials. Alcohol Clin Exp Res 2010; 34: 2022–2034.
37. Delucchi K. L., Weisner C. Transitioning into and out of problem drinking across seven years. J Stud Alcohol Drugs 2010; 71: 210–218.
38. Spielberger C. D. State-Trait Anxiety Inventory. Hoboken, NJ: John Wiley & Sons, Inc.; 2010.
39. Marsot A., Imbert B., Alvarez J. C., Grassin-Delyle S., Jaquet I., Lançon C. et al. High variability in the exposure of baclofen in alcohol-dependent patients. Alcohol Clin Exp Res 2014; 38: 316–321.
40. Pastor A., Jones D. M., Currie J. High-dose baclofen for treatment-resistant alcohol dependence. J Clin Psychopharmacol 2012; 32: 266–268.
41. Rigal L., Alexandre-Dubroeucq C., de Beaurepaire R., Le Jeunne C., Jaury P. Abstinence and ‘low-risk’ consumption 1 year after the initiation of high-dose baclofen: a retrospective study among ‘high-risk’ drinkers. Alcohol Alcohol 2012; 47: 439–442.
42. De Beaurepaire R. Suppression of alcohol dependence using baclofen: a 2-year observational study of 100 patients. Front Psychiatry 2012; 3: 3389.
43. Müller C. A., Geisel O., Pelz P., Higl V., Krüger J., Stickel A. High-dose baclofen for the treatment of alcohol dependence (BACLAD study): a randomized, placebo-controlled trial. Eur Neuropsychopharmacol 2015; 25: 1167–1177.
44. Beraha E. M., Salemik E., Goudriaan A. E., Bakker A., de Jong D., Smits N. Efficacy and safety of high-dose baclofen for the treatment of alcohol dependent: a multicentre, randomized, double-blind controlled trial. Eur Neuropsychopharmacol 2016; 25: 1950–1959.